Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification — OMS302-ILR-003

Intraocular Lens Replacement Clinical Trial

Official title:
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of OMS302 (the study drug) for maintaining intraoperative mydriasis in individuals undergoing Intraocular Lens Replacement (ILR) surgery.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intraocular Lens Replacement

Clinical Trial Details

NCT number	NCT01454063
Study type	Interventional
Source	Omeros Corporation
Contact
Status	Completed
Phase	Phase 3
Start date	September 2011
Completion date	March 2012

View Details

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT02093689` - Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery	Phase 3
	Completed	`NCT01579565` - Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification	Phase 3